MRS Measurement of Glutamate and GABA Metabolism in Brain

Sponsor

National Institute of Mental Health (NIMH) (NIH)

Overall Status

Recruiting

CT.gov ID

NCT00109174

Collaborator

(none)

200

Enrollment

Location

Arm

210.1

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will use magnetic resonance spectroscopy (MRS) to measure in the brain the transfer of [13]C as it is naturally metabolized from glucose to specific chemical transmitters. From this method, we can measure the rate of production of an important excitatory neurotransmitter (glutamate) as well as an inhibitory neurotransmitter (GABA)....

Condition or Disease	Intervention/Treatment	Phase
Normal Physiology	Device: 3T and 7T device	N/A

Detailed Description

13C is a stable (i.e., non-radioactive) isotope of carbon with a natural abundance of ~1%. Following infusion of [13C]glucose and/or [13C]acetate, in vivo MRS (magnetic resonance spectroscopy) can monitor the rate of flux of the 13C atom from glucose and/or acetate to glutamate to glutamine. Thus, this procedure can provide measure of glutamate (GLU) and glutamine (GLN) turnover in brain. We have established parameters to obtain these measurements in nonhuman primate brain. The current protocol seeks approval to optimize MRS parameters and to develop new MRS techniques for human brain using the GE 3T, the Siemens 3T, and the Siemens 7T device.

Study population: All subjects will be aged 18 65 years, without serious medical illnesses and meet criteria listed in Section VI A.

Design: Subjects will receive either oral administration of [13C]glucose or an intravenous infusion of [13C]glucose and/or [13C]acetate to approximately double their plasma glucose levels. The plasma acetate level will remain within the physiological range observed in humans (Lebon et al, 2002). While lying in the 3T or 7T device, serial data acquisitions will be obtained over ~2 h to optimize the experimental conditions so as to measure the 13C signals from GLU, GLN and other metabolisms in brain.

Outcome measures: The primary goal of this study is to measure GLU/GLN turnover in brain. With no additional data acquisition, we can also obtain information on the synthesis of GABA, the major inhibitory neurotransmitter in brain. GLU is converted to GABA via the enzyme glutamic acid decarboxylase (GAD). While monitoring the transfer of 13C signal from GLU to GLN, we can simultaneously measure the transfer of 13C signal from GLU to GABA and thereby measure the activity of GAD (Li et al 2005). In addition to directly measure 13C signals, 13C labeling to brain metabolites can also be measured indirectly by detecting proton MRS during infusion of [13C]glucose and/or [13C]acetate.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

200 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Basic Science

Official Title:

MRS (Magnetic Resonance Spectroscopy) Measurement of Glutamate and GABA Metabolism in Brain

Actual Study Start Date :

Sep 6, 2006

Anticipated Primary Completion Date :

Jan 11, 2024

Anticipated Study Completion Date :

Mar 11, 2024

Arms and Interventions

Arm	Intervention/Treatment
Other: One arm Subjects receive the same test	Device: 3T and 7T device 3T and 7T device

Arm

Intervention/Treatment

Other: One arm

Subjects receive the same test

Device: 3T and 7T device

3T and 7T device

Outcome Measures

Primary Outcome Measures

The primary outcome is the quality of the MR spectroscopy which includes spectrum signal-to-noise (SNR)\ ratio, spectral lineshape, linewidth, and resolution. [prospective and ongoing]
To obtain more accurate and reliable MRS data from the human brain

Secondary Outcome Measures

The secondary outcome is the performance improvements of the scanner hardware, software and methodology [prospective and ongoing]
To obtain more accurate and reliable MRS data from the human brain.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

INCLUSION CRITERIA:
18-65 years of age
able to give written informed consent
healthy based on medical history and physical exam
enrolled in Protocol 01-M-0254 or Protocol 17-M-0181

EXCLUSION CRITERIA:

Any current Axis 1 diagnosis
Clinically significant laboratory abnormalities
Positive HIV test
Metallic foreign bodies that would be affected by the magnetic resonance imaging (MRI) magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan.
History of neurological illness or injury with the potential to affect study data interpretation, such as multiple sclerosis, Parkinson s disease, seizure disorder or traumatic brain injury
Prescription psychotropic medication; drug free less than 8 weeks (anticholinergics, benzodiazepine, fluoxetine, antipsychotics, and anticonvulsants)
Serious medical illness as determined from H&P or laboratory testing including Diabetes
Inability to lie flat on camera bed for about two and a half hours
Pregnant or breastfeeding
Current substance use disorder based on DSM-5
NIMH employees and staff and their immediate family members will be excluded from the study per NIMH policy.